Plain-English translation of NCT06391892 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tests whether a simple blood test—looking for traces of cancer DNA in your blood—can help doctors make better treatment decisions for localized pancreatic cancer. Right now, doctors decide between surgery first or chemotherapy first based mainly on imaging scans and blood markers. This study asks whether this new blood test can give doctors earlier, more accurate information about whether cancer is likely to come back, so they can choose the best treatment plan for you.
Pancreatic cancer has very poor survival rates, and many patients have early recurrence even when doctors thought their cancer was fully contained. The researchers believe this blood test can detect hidden cancer spread earlier than current imaging methods, allowing doctors to offer chemotherapy upfront to patients at highest risk rather than waiting to see if cancer returns after surgery.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a blood sample taken before your planned pancreatic cancer treatment. In one group, doctors will use the blood test results to decide whether you need chemotherapy before surgery or can proceed directly to surgery; in the other group, your doctor will make this decision using standard methods as usual. You will be followed over time to see how well the blood test predicts your treatment response and whether your cancer comes back.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Austria